Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model

11 Feb 2021

Abstract excerpt

BACKGROUND: The World Health Organization recommends standardised treatment durations for patients with tuberculosis (TB). We identified and validated a host-RNA signature as a biomarker for individualised therapy durations for patients with drug-susceptible (DS)- and multidrug-resistant (MDR)-TB. METHODS: Adult patients with pulmonary TB were prospectively enrolled into five independent cohorts in Germany and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diagnosis and treatment of tuberculosis
Share to Immune responses and vaccinations
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33574078
DOI: 10.1183/13993003.03492-2020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic modelPMID 33574078Read ↗

A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosisSemantic proximity Read ↗

Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in BrazilSemantic proximity Read ↗

Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatmentSemantic proximity Read ↗

A new blood-based RNA signature (R9), for monitoring effectiveness of tuberculosis treatment in a South Indian longitudinal cohortSemantic proximity Read ↗

Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatmentSemantic proximity Read ↗

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trialSemantic proximity Read ↗

RISK6 as a Translational Host Transcriptomic Signature for Tuberculosis Diagnosis, Treatment Monitoring, and Risk StratificationSemantic proximity Read ↗

Common gene signature model discovery and systematic validation for TB prognosis and response to treatmentSemantic proximity Read ↗

Circulating Cell-Free RNA in Blood as a Host Response Biomarker for the Detection of TuberculosisSemantic proximity Read ↗

Resolution of blood RNA signatures fails to discriminate sputum culture status after eight weeks of tuberculosis treatmentSemantic proximity Read ↗

A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency VirusSemantic proximity Read ↗

RISK6, a universal 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.